Skip to main content

Immune Response BioPharma, Inc.

Drug Discovery
Press Releases
Investor Relations
Stock Information
Executive Team
Scientific Board
Clinical Trials
REMUNE Vaccine
REMUNE Rx Co-pay Card
Remune Pediatric
RemuneVax Vaccine
NeuroVax Vaccine
RAVAX Vaccine
RAVAX II Vaccine
Zorcell Vaccine
Rare Diseases
Vaccines Direct
Bio Defense
Immune Response Hospital
Orchestra Therapeutics
Research Donations
About Us
Corporate Filings
Corporate ByLaws
Transfer Agent
Contact Us
Email Alerts
Member Login
Site Map
 Immune Response BioPharma, Inc. TM      Copyright © 2010-2019

Press Releases:

Immune Response BioPharma, Inc. Remune Revenues seen at $36-72M on First Year of Right to Try Compassionate Care Use of Remune HIV Vaccine Pricing Cost Cap at Approximately $3000 per Injection
Feb 17th 2018

Immune Reponse BioPharma, Inc. Guarantees Remune BLA Approval for Pediatric FDA Orphan Indication 
FDA Orphan Designated Remune Development on Track.: IRBP the #1 Leading HIV Vaccine Corp Globally
November 25th 2017

Immune Response BioPharma, Inc. Thankful @Thanksgiving for Remune First HIV Vaccine 
November 23rd 2017 

Immune Response BioPharma, Inc. The Eagle has Landed Remune Pediatric Booster HIV Indication  BLA Filed w CBER FDA on Track One Small Step for Man its One Giant Leap for Mankind
October 23rd 2017

Immune Response BioPharma, Inc. Corporate Update on Track to Meet All Company Goals Remune & 
NeuroVax Development Ahead of Schedule
July 7th 2017

Immune Response BioPharma, Inc.  Commences $25B Class Action on Behalf of Remune HIV Patients
April 13th 2017 Class Action Lawsuit info website under construction 

Immune Response BioPharma, Inc. Files New BLA for FDA Orphan Designated Pediatric HIV Indication: 
IRBP's 2nd Remune HIV Vaccine Product Filed for FDA BLA Approval
March 31st 2017      More:

December 27th 2016    More: PR PDF

Immune Response BioPharma, Inc. Announces a Lottery System will be Utilized for Remune to Ensure Fairness for Initial Commercial Batches or Compassionate Use Under New IND Filing Once Vaccine is Made Available  
December 27th 2016

Immune Response BioPharma, Inc, Highlights FDA SPMS Fast Track & FDA Orphan Pediatric T Cell MS Vaccine NeuroVax First in Class & Best in Class Last Standing Treatment for SPMS in Development 
December 12th 2016

Immune Response BioPharma, Inc. Announces HIV Experts & Thought Leaders Conclusion: Remune "Highly Immunogenic"
November 19th 2016

Immune Response BioPharma, Inc. Issues Cease & Desist Letters to IP Infringers'; Warns Pharmaceutical Industry Against Patent Infringement & Consequences, IRBP will Vigorously Defend & Block any Use of it's IP of the Patented NeuroVax Technology & MS T cell Vaccination Platform
September 18th 2016

Immune Response BioPharma, Inc. Files Amended BLA for Remune with the FDA
August 6th 2016   

Immune Response BioPharma, Inc.  Reserves Stock Symbol IRBP on NASDAQ
February 13th 2016   More:    


Immune Response BioPharma, Inc.TM 
Copyright (C) 2010-2019  All Rights Reserved